Dietary Sodium, Oxidative Stress, and Pulsatile Hemodynamics
NCT04233957
Recruiting
High sodium diets impair vascular function, which may influence the work of the heart. This investigation is designed to determine if this change in vascular function results in a greater workload in the heart and if people who regularly exercise are protected from these effects.
Gender:
All
Ages:
Between 21 years and 45 years
Trial Updated:
11/28/2023
Locations: Department of Kinesiology and Applied Physiology, University of Delaware, Newark, Delaware
Conditions: Sodium Excess
Register for Updates
Determinants of Changes in Arterial Load Following Exercise
NCT05820243
Recruiting
The goal of this study is to learn about how blood vessel dilation after exercise effects pulse wave reflection and influences the function of the heart in healthy young adults. The main question it aims to answer is: Are post-exercise decreases in reflected pulse waves due to a decrease in the stiffness of large arteries in the leg or an increase in leg blood flow? Participants will exercise on a stationary bicycle at a moderate intensity for 1 hour during two laboratory visits. Participants wi... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
11/27/2023
Locations: Department of Kinesiology and Applied Physiology, University of Delaware, Newark, Delaware
Conditions: Post-Exercise Hypotension
Register for Updates
Non-Invasive Measurement of Pulmonary Dysfunction in Children With Cerebral Palsy
NCT05791877
Recruiting
This proposal addresses pulmonary dysfunction in severe cerebral palsy by using a novel non-invasive respiratory sensor. The two aims of the project are to 1) provide a screening tool to detect respiratory distress and 2) Find a correlation between the degree of pulmonary dysfunction and scoliosis in children with cerebral palsy.
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
11/27/2023
Locations: Nemours Children's Hospital, Wilmington, Delaware
Conditions: Cerebral Palsy
Register for Updates
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325
Recruiting
The study compares two medicines for treatment of children born small and who stay small, or with Turner Syndrome, Noonan Syndrome, or idiopathic short stature. The purpose of the study is to see how well treatment with somapacitan works compared to treatment with Norditropin®. Somapacitan is a new medicine, and Norditropin® is a medicine doctors can already prescribe in some countries. The study will last for about 3 years. The participants will either get somapacitan once a week for 3 years or... Read More
Gender:
All
Ages:
Between 2 years and 10 years
Trial Updated:
11/27/2023
Locations: Novo Nordisk Investigational Site, Wilmington, Delaware
Conditions: SGA, Turner Syndrome, Noonan Syndrome, ISS
Register for Updates
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
11/27/2023
Locations: Nemours Children's Health, Wilmington, Delaware
Conditions: Pediatric Migraine
Register for Updates
Casting vs Bracing for Idiopathic Early-Onset Scoliosis
NCT04500041
Recruiting
Comparison of casting and bracing for the treatment of idiopathic early onset scoliosis
Gender:
All
Ages:
Between 12 months and 36 months
Trial Updated:
11/27/2023
Locations: Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware
Conditions: Scoliosis Idiopathic, Early-Onset Scoliosis Deformity of Spine
Register for Updates
African American Families Fighting Parental Cancer Together
NCT03567330
Recruiting
The purpose of this study is to test the usefulness of a family-based program for African American parents/primary caregivers with newly diagnosed solid tumor cancer and their adolescent children. The program is designed to promote family communication reduce and depressive symptoms for adolescence.
Gender:
All
Ages:
11 years and above
Trial Updated:
11/27/2023
Locations: Helen F Graham Cancer Center & Research Institute at Christiana Care, Newark, Delaware
Conditions: Depressive Symptoms, Anxiety, Parental Stress
Register for Updates
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279
Recruiting
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzyme... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Beebe South Coastal Health Campus, Frankford, Delaware
Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Register for Updates
Vascular Effects of Dietary Salt in Humans With Salt-Resistant Blood Pressure
NCT03424993
Recruiting
The purpose of this study is to determine the effects of dietary salt restriction on central hemodynamics and vascular function in men and women with salt resistant blood pressure.
Gender:
All
Ages:
Between 21 years and 45 years
Trial Updated:
11/27/2023
Locations: Department of Kinesiology and Applied Physiology, University of Delaware, Newark, Delaware
Conditions: Healthy
Register for Updates
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Glasgow Surgery Center, Newark, Delaware
Conditions: Lumbar Spinal Stenosis
Register for Updates
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
NCT04333576
Recruiting
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endomet... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
11/24/2023
Locations: Reproductive Assoc of Delaware /ID# 227764, Newark, Delaware
Conditions: Endometriosis
Register for Updates
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069
Recruiting
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form... Read More
Gender:
All
Ages:
Between 180 days and 22 years
Trial Updated:
11/23/2023
Locations: Alfred I duPont Hospital for Children, Wilmington, Delaware
Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Register for Updates